董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
John K. Paglia Independent Director 59 18.00万美元 未持股 2026-02-12
Daniel Weiner Board Chair and Independent Director 76 19.35万美元 未持股 2026-02-12
Sharlene Evans Independent Director 62 17.55万美元 未持股 2026-02-12
Walter S. Woltosz Independent Director 80 15.53万美元 未持股 2026-02-12

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Shawn O'Connor Chief Executive Officer 67 109.66万美元 未持股 2026-02-12
Will Frederick Chief Financial Officer and Executive Vice-President 63 53.47万美元 未持股 2026-02-12
Jill Fiedler Kelly President Services Solutions 57 46.51万美元 未持股 2026-02-12
Jonathan Chauvin Co-Chief Product and Technology Officer 44 未披露 未持股 2026-02-12
Josh Fohey Chief Operating Officer 43 35.83万美元 未持股 2026-02-12
Erik Guffrey Co-Chief Product and Technology Officer 45 未披露 未持股 2026-02-12
Viera Lukacova Chief Scientific Officer 51 未披露 未持股 2026-02-12
John A. DiBella Chief Revenue Officer 47 48.90万美元 未持股 2026-02-12

董事简历

中英对照 |  中文 |  英文
John K. Paglia

JohnK.Paglia自2014年12月3日起担任公司董事和审计委员会主席。他也是CAL-X Business Accelerator,Inc.(30个再生健康技术初创公司)的董事兼审计和财务委员会主席、非营利的加州业余曲棍球协会的董事,以及Pepperdine University的高级副院长兼金融学教授。Paglia博士拥有金融学博士学位,工商管理硕士学位,金融学学士学位,是一名注册会计师,特许金融分析师,金融风险经理,并获得了NACD董事资格认证™;由美国企业董事协会认证。他曾担任Pepperdine University的多种领导职务(2000年加入学院以来),包括Pepperdine Private Capital Markets项目的创始董事、认证董事、会计和财务部门主席、兼职项目副院长、Peate Institute for Entrepreneurship的执行董事,并目前以高级副院长的身份监管商学院教员。因为他对私人资本市场的开创性研究,他于2016年获得全美注册估值师和分析师协会颁发的行业泰坦奖并购顾问联盟奖,并于2012年获得格兰特桑顿年度思想领袖奖。以及2011年企业成长协会(Association for Corporate Growth)的卓越并购奖(Excellence in M&A Award)。2016年,他还与美国国会图书馆(Library of Congress)签约,担任私募股权和风险投资专家,研究小企业管理局SBIC私募股权计划的经济影响。2019年,他应美国众议院小企业委员会的要求,在听证会上提供了国会专家证词:SBA管理评论:小企业投资公司计划。


John K. Paglia has served as one of directors and audit committee chair since December 3, 2014. Dr. Paglia is also an independent board director and audit committee chair for Aeluma, Inc. (NASDAQ: ALMU), and as an advisor to venture capital firms and startup companies. After 25 years with Pepperdine University's Graziadio School of Biness, serving in a variety of academic and leadership roles, John retired in July 2025 with the honorary title of Professor Emerit of Finance. He also served as a consultant to the Library of Congress and the U.S. Congress, where he testified as an expert on the Small Biness Administration's private equity and venture capital program. John is a recipient of several prestigio indtry awards for his work on the financing and capital markets.
JohnK.Paglia自2014年12月3日起担任公司董事和审计委员会主席。他也是CAL-X Business Accelerator,Inc.(30个再生健康技术初创公司)的董事兼审计和财务委员会主席、非营利的加州业余曲棍球协会的董事,以及Pepperdine University的高级副院长兼金融学教授。Paglia博士拥有金融学博士学位,工商管理硕士学位,金融学学士学位,是一名注册会计师,特许金融分析师,金融风险经理,并获得了NACD董事资格认证™;由美国企业董事协会认证。他曾担任Pepperdine University的多种领导职务(2000年加入学院以来),包括Pepperdine Private Capital Markets项目的创始董事、认证董事、会计和财务部门主席、兼职项目副院长、Peate Institute for Entrepreneurship的执行董事,并目前以高级副院长的身份监管商学院教员。因为他对私人资本市场的开创性研究,他于2016年获得全美注册估值师和分析师协会颁发的行业泰坦奖并购顾问联盟奖,并于2012年获得格兰特桑顿年度思想领袖奖。以及2011年企业成长协会(Association for Corporate Growth)的卓越并购奖(Excellence in M&A Award)。2016年,他还与美国国会图书馆(Library of Congress)签约,担任私募股权和风险投资专家,研究小企业管理局SBIC私募股权计划的经济影响。2019年,他应美国众议院小企业委员会的要求,在听证会上提供了国会专家证词:SBA管理评论:小企业投资公司计划。
John K. Paglia has served as one of directors and audit committee chair since December 3, 2014. Dr. Paglia is also an independent board director and audit committee chair for Aeluma, Inc. (NASDAQ: ALMU), and as an advisor to venture capital firms and startup companies. After 25 years with Pepperdine University's Graziadio School of Biness, serving in a variety of academic and leadership roles, John retired in July 2025 with the honorary title of Professor Emerit of Finance. He also served as a consultant to the Library of Congress and the U.S. Congress, where he testified as an expert on the Small Biness Administration's private equity and venture capital program. John is a recipient of several prestigio indtry awards for his work on the financing and capital markets.
Daniel Weiner

Daniel Weiner于2017年5月1日被任命为公司董事。Weiner博士毕业于肯塔基大学(University of Kentucky),获得数理统计学博士学位,重点是舱室建模。Weiner博士担任美国食品药品监督管理局(U.S.Food and Drug Administration FDA)药物动力学建模与生物等效性评估的专家顾问。Weiner博士曾在Merrell Dow Pharmaceuticals、Statistics Consultants,Inc.、Syntex Development Research、Certara Inc.、Pharsight Corp.、Quintiles和IVAX Research等公司担任高级管理职位。Weiner博士是北卡罗来纳大学(University of North Carolina)药学院(School of Pharmaceutical)药物治疗与实验治疗学部的兼职教授。他是PK/PD建模软件Winnon Lin家族的原始设计师/作者,也是药代动力学和药效学数据分析:概念和应用的合著者。Weiner博士曾担任Dilisym Services,Inc.(“;Dilisym”;)的董事会成员,该公司现为SimulationsPlus,Inc.的子公司。


Daniel Weiner has been a director of the Company since May 1, 2017, served as Lead Independent Director of the Board from October 20, 2022, to December 17, 2024, and was appointed as Chairman of the Board on December 17, 2024. Dr. iner is also an independent director of Simmunone, Inc. Dr. iner graduated from the University of Kentucky with a doctoral degree in Mathematical Statistics, with an emphasis on compartmental modeling. Dr. iner has served as an expert consultant to the U.S. Food and Drug Administration ("FDA") on pharmacokinetic modeling and bioequivalence assessment and is the 2022 American Society for Clinical Pharmacology & Therapeutics ("ASCPT") recipient of the Sheiner Beal Award in Pharmacometrics. Dr. iner is a Fellow of the American Statistical Association ("ASA"). Dr. iner has held senior management positions at companies such as Merrell Dow Pharmaceuticals; Statistical Consultants, Inc. (founder); Syntex Development Research; Certara Inc.; Pharsight Corp.; Quintiles, Inc. (now IQVIA); and IVAX Research, where he had operational responsibilities as ll as assisting with M&A activities. Dr. iner is an Adjunct Professor with the Division of Pharmacotherapy and Experimental Therapeutics in the School of Pharmacy, University of North Carolina. He is the original designer/author of the WinNonlin family of PK/PD Modeling Software and is the co author of Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. Dr. iner previoly served as a Board member of DILIsym Services, Inc. ("DILIsym"), which was merged into the Company in September 2021.
Daniel Weiner于2017年5月1日被任命为公司董事。Weiner博士毕业于肯塔基大学(University of Kentucky),获得数理统计学博士学位,重点是舱室建模。Weiner博士担任美国食品药品监督管理局(U.S.Food and Drug Administration FDA)药物动力学建模与生物等效性评估的专家顾问。Weiner博士曾在Merrell Dow Pharmaceuticals、Statistics Consultants,Inc.、Syntex Development Research、Certara Inc.、Pharsight Corp.、Quintiles和IVAX Research等公司担任高级管理职位。Weiner博士是北卡罗来纳大学(University of North Carolina)药学院(School of Pharmaceutical)药物治疗与实验治疗学部的兼职教授。他是PK/PD建模软件Winnon Lin家族的原始设计师/作者,也是药代动力学和药效学数据分析:概念和应用的合著者。Weiner博士曾担任Dilisym Services,Inc.(“;Dilisym”;)的董事会成员,该公司现为SimulationsPlus,Inc.的子公司。
Daniel Weiner has been a director of the Company since May 1, 2017, served as Lead Independent Director of the Board from October 20, 2022, to December 17, 2024, and was appointed as Chairman of the Board on December 17, 2024. Dr. iner is also an independent director of Simmunone, Inc. Dr. iner graduated from the University of Kentucky with a doctoral degree in Mathematical Statistics, with an emphasis on compartmental modeling. Dr. iner has served as an expert consultant to the U.S. Food and Drug Administration ("FDA") on pharmacokinetic modeling and bioequivalence assessment and is the 2022 American Society for Clinical Pharmacology & Therapeutics ("ASCPT") recipient of the Sheiner Beal Award in Pharmacometrics. Dr. iner is a Fellow of the American Statistical Association ("ASA"). Dr. iner has held senior management positions at companies such as Merrell Dow Pharmaceuticals; Statistical Consultants, Inc. (founder); Syntex Development Research; Certara Inc.; Pharsight Corp.; Quintiles, Inc. (now IQVIA); and IVAX Research, where he had operational responsibilities as ll as assisting with M&A activities. Dr. iner is an Adjunct Professor with the Division of Pharmacotherapy and Experimental Therapeutics in the School of Pharmacy, University of North Carolina. He is the original designer/author of the WinNonlin family of PK/PD Modeling Software and is the co author of Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. Dr. iner previoly served as a Board member of DILIsym Services, Inc. ("DILIsym"), which was merged into the Company in September 2021.
Sharlene Evans

Sharlene Evans于2021年12月1日被任命为公司董事。埃文斯女士获得了奥本大学的工业工程学士学位,并毕业于普渡大学,获得了工业工程硕士学位。Evans女士在为财富500强客户执行复杂的多站点组织的大型改进项目方面有着良好的记录。她目前担任变革管理和可持续发展咨询公司Myrle Consulting Group的首席人力官,该公司现在是埃森哲的一部分,自2019年7月起担任该职位。在Myrtle,她负责内部人员流程以支持Myrtle员工,她还领导团队负责开发和交付人员和组织能力以及为Myrtle客户提供的服务。在加入Myrtle之前,Evans女士于2016年1月至2019年6月担任SSA&Company人事和组织副总裁。她之前的咨询经验还包括Hitachi Consulting,Celerant Consulting和Ernst&Young Consulting。


Sharlene Evans received a Bachelor's degree in Indtrial Engineering from Auburn University, and graduated from Purdue University with a Master's degree in Indtrial Engineering. Ms. Evans has a proven track as an executive leading the Human Resces function as ll as a consultant in executing large scale improvement projects across complex, multisite organizations for Fortune 500 clients. She currently serves as a Partner/People Leader for sfor Rubicon Management Consultants. She was previoly Chief People Officer Americas for 'EFESO Management Consultants, a Principal Director at Accenture, where she led deployment of capabilities in organization design, change management, and leadership development as part of client transformation projects. Prior to Accenture's acquisition of Myrtle Consulting Group, a change management and operations consulting firm, Ms. Evans served as the Chief People Officer at Myrtle Consulting Group, where she was responsible for the internal people processes to support Myrtle employees. Ms. Evans also led the team responsible for the development and delivery of the people and organization capabilities and service offerings provided to Myrtle clients. Prior to joining Myrtle, Ms. Evans was the Vice President of People and Organization at SSA & Company from January 2016 to June 2019. Her prior consulting experience also includes Hitachi Consulting, Celerant Consulting, and Ernst & Young Consulting. She also held indtry roles at Eli Lilly and Company and Dell.
Sharlene Evans于2021年12月1日被任命为公司董事。埃文斯女士获得了奥本大学的工业工程学士学位,并毕业于普渡大学,获得了工业工程硕士学位。Evans女士在为财富500强客户执行复杂的多站点组织的大型改进项目方面有着良好的记录。她目前担任变革管理和可持续发展咨询公司Myrle Consulting Group的首席人力官,该公司现在是埃森哲的一部分,自2019年7月起担任该职位。在Myrtle,她负责内部人员流程以支持Myrtle员工,她还领导团队负责开发和交付人员和组织能力以及为Myrtle客户提供的服务。在加入Myrtle之前,Evans女士于2016年1月至2019年6月担任SSA&Company人事和组织副总裁。她之前的咨询经验还包括Hitachi Consulting,Celerant Consulting和Ernst&Young Consulting。
Sharlene Evans received a Bachelor's degree in Indtrial Engineering from Auburn University, and graduated from Purdue University with a Master's degree in Indtrial Engineering. Ms. Evans has a proven track as an executive leading the Human Resces function as ll as a consultant in executing large scale improvement projects across complex, multisite organizations for Fortune 500 clients. She currently serves as a Partner/People Leader for sfor Rubicon Management Consultants. She was previoly Chief People Officer Americas for 'EFESO Management Consultants, a Principal Director at Accenture, where she led deployment of capabilities in organization design, change management, and leadership development as part of client transformation projects. Prior to Accenture's acquisition of Myrtle Consulting Group, a change management and operations consulting firm, Ms. Evans served as the Chief People Officer at Myrtle Consulting Group, where she was responsible for the internal people processes to support Myrtle employees. Ms. Evans also led the team responsible for the development and delivery of the people and organization capabilities and service offerings provided to Myrtle clients. Prior to joining Myrtle, Ms. Evans was the Vice President of People and Organization at SSA & Company from January 2016 to June 2019. Her prior consulting experience also includes Hitachi Consulting, Celerant Consulting, and Ernst & Young Consulting. She also held indtry roles at Eli Lilly and Company and Dell.
Walter S. Woltosz

Walter S. Woltosz是本公司的联合创始人,自1996年6月以来一直担任本公司的董事,包括1996年7月17日至2024年12月17日担任董事会主席。作为70多篇技术出版物、会议论文和两本书章节的作者/合著者,他在药物动力学和药物研究机器学习方法方面的专业知识得到了广泛认可。他也是位于阿拉巴马州伯明翰的Vulcan Line Tools Corporation的重要投资者和独立董事。他于2024年3月21日被阿拉巴马州参议院确认为奥本大学的受托人,任期7年。在共同创立公司之前,Woltosz博士曾在美国空军担任导弹系统分析师;作为联邦航空管理局的电子工程师;诺斯罗普服务公司为航天飞机上升轨迹开发仿真/优化软件;并在Thiokol公司、空军火箭推进实验室和联合技术公司化学系统部担任火箭发动机工程师。1981年,他创立了Words+, Inc.,一家设计、制造和销售基于计算机的通信系统的公司,包括由斯蒂芬·霍金教授编写的前身为Simulations Plus, Inc.的系统。Woltosz博士拥有杰出的奥本工程师奖,奥本校友会终身成就奖,并且是阿拉巴马州工程名人堂的成员。他是奥本校友工程委员会、工程楔石协会、工程鹰协会、工程Ginn协会以及1856协会和Pat Dye协会的成员。Woltosz博士拥有奥本大学(Auburn University)的航空航天工程学士学位和硕士学位,以及奥本大学(Auburn University)的荣誉科学博士学位,以及亨茨维尔阿拉巴马大学(University of Alabama)的行政科学硕士学位。


Walter S. Woltosz is a cofounder of the Company, served as its Chief Executive Officer until June 26, 2018, and has served as a director of the Company since June 1996, including as Chairman of the Board from July 17, 1996 to December 17, 2024. As author/coauthor of over 70 technical publications, conference papers, and two book chapters over 25 years, his expertise in pharmacokinetics and machine learning methodology for pharmaceutical research is ll recognized. He is also a significant investor in, and independent director of, the Vulcan Line Tools Inc. in Birmingham, Alabama and of Protector Innovations, Inc. in Auburn, Alabama.. He was confirmed as a Trtee for Auburn University by the Alabama Senate on March 21, 2024, for a seven year term that will expire on March 20, 2031. Prior to cofounding the Company, Dr. Woltosz served in the United States Air Force as a missile systems analyst; as an electronics engineer with the Federal Aviation Administration; with Northrop Services developing simulation/optimization software for the space shuttle ascent trajectory; and with the Thiokol corporation, Air Force Rocket Propulsion Laboratory, and United Technologies Corporation Chemical Systems Division as a rocket motor engineer. In 1981, he established Words+, Inc., a company that designs, manufactures, and sells computer based communication systems, including the system formerly ed by Professor Stephen Hawking. Dr. Woltosz holds the Distinguished Auburn Engineer Award, Auburn Alumni Association Lifetime Achievement Award, and is a member of the State of Alabama Engineering Hall of Fame. He is a member of the Auburn Alumni Engineering Council, the Engineering Keystone Society, the Engineering Eagles Society, and the Engineering Ginn Society, as ll as the 1856 Society and the Pat Dye Society. Dr. Woltosz holds Bachelor's and Master's degrees in aerospace engineering, and an honorary Doctor of Science (D.Sc.) from Auburn University, as ll as a Master's degree in administrative science from the University of Alabama, Huntsville.
Walter S. Woltosz是本公司的联合创始人,自1996年6月以来一直担任本公司的董事,包括1996年7月17日至2024年12月17日担任董事会主席。作为70多篇技术出版物、会议论文和两本书章节的作者/合著者,他在药物动力学和药物研究机器学习方法方面的专业知识得到了广泛认可。他也是位于阿拉巴马州伯明翰的Vulcan Line Tools Corporation的重要投资者和独立董事。他于2024年3月21日被阿拉巴马州参议院确认为奥本大学的受托人,任期7年。在共同创立公司之前,Woltosz博士曾在美国空军担任导弹系统分析师;作为联邦航空管理局的电子工程师;诺斯罗普服务公司为航天飞机上升轨迹开发仿真/优化软件;并在Thiokol公司、空军火箭推进实验室和联合技术公司化学系统部担任火箭发动机工程师。1981年,他创立了Words+, Inc.,一家设计、制造和销售基于计算机的通信系统的公司,包括由斯蒂芬·霍金教授编写的前身为Simulations Plus, Inc.的系统。Woltosz博士拥有杰出的奥本工程师奖,奥本校友会终身成就奖,并且是阿拉巴马州工程名人堂的成员。他是奥本校友工程委员会、工程楔石协会、工程鹰协会、工程Ginn协会以及1856协会和Pat Dye协会的成员。Woltosz博士拥有奥本大学(Auburn University)的航空航天工程学士学位和硕士学位,以及奥本大学(Auburn University)的荣誉科学博士学位,以及亨茨维尔阿拉巴马大学(University of Alabama)的行政科学硕士学位。
Walter S. Woltosz is a cofounder of the Company, served as its Chief Executive Officer until June 26, 2018, and has served as a director of the Company since June 1996, including as Chairman of the Board from July 17, 1996 to December 17, 2024. As author/coauthor of over 70 technical publications, conference papers, and two book chapters over 25 years, his expertise in pharmacokinetics and machine learning methodology for pharmaceutical research is ll recognized. He is also a significant investor in, and independent director of, the Vulcan Line Tools Inc. in Birmingham, Alabama and of Protector Innovations, Inc. in Auburn, Alabama.. He was confirmed as a Trtee for Auburn University by the Alabama Senate on March 21, 2024, for a seven year term that will expire on March 20, 2031. Prior to cofounding the Company, Dr. Woltosz served in the United States Air Force as a missile systems analyst; as an electronics engineer with the Federal Aviation Administration; with Northrop Services developing simulation/optimization software for the space shuttle ascent trajectory; and with the Thiokol corporation, Air Force Rocket Propulsion Laboratory, and United Technologies Corporation Chemical Systems Division as a rocket motor engineer. In 1981, he established Words+, Inc., a company that designs, manufactures, and sells computer based communication systems, including the system formerly ed by Professor Stephen Hawking. Dr. Woltosz holds the Distinguished Auburn Engineer Award, Auburn Alumni Association Lifetime Achievement Award, and is a member of the State of Alabama Engineering Hall of Fame. He is a member of the Auburn Alumni Engineering Council, the Engineering Keystone Society, the Engineering Eagles Society, and the Engineering Ginn Society, as ll as the 1856 Society and the Pat Dye Society. Dr. Woltosz holds Bachelor's and Master's degrees in aerospace engineering, and an honorary Doctor of Science (D.Sc.) from Auburn University, as ll as a Master's degree in administrative science from the University of Alabama, Huntsville.

高管简历

中英对照 |  中文 |  英文
Shawn O'Connor

Shawn O’Connor于2018年6月加入公司,担任首席执行官。从2011年至2018年,奥康纳先生担任Entelos的首席执行官,总裁兼董事,Entelos是一家为制药药物开发市场提供独特的定量系统药理软件和服务的提供商。从2002年到2009年,O’Connor先生担任Pharsight Corporation的首席执行官,总裁兼董事长,该公司是一家软件产品和服务的开发商和营销商,帮助制药和生物技术公司改善其药物开发和商业化的决策。从1995年到2000年,奥康纳先生在QRS公司担任多个职位,包括首席财务官、总裁兼首席运营官。1988年至1994年,O’Connor先生在Diasonics,Inc.担任多个职位,包括首席财务官。O’Connor先生在加州大学伯克利分校(University of California at Berkeley)获得工商管理理学学士学位,并在斯坦福大学商学院(Stanford University Graduate School of Business)完成高管教育课程。


Shawn O'Connor,joined the Company in June 2018 as Chief Executive Officer. Mr. O'Connor has more than 31 years of experience in high technology executive management. From 2011 to 2018, Mr. O'Connor was Chief Executive Officer, President, and a director of Entelos Holding Corp., a provider of unique quantitative systems pharmacology software and services to the pharmaceutical drug development market. From 2002 to 2009, Mr. O'Connor served as Chief Executive Officer, President, and Chairman of Pharsight Corporation, a developer and marketer of software products and services that help pharmaceutical and biotechnology companies improve their decision-making in drug development and commercialization. From 1995 to 2000, Mr. O'Connor was with QRS Corporation in various positions including Chief Financial Officer and President and Chief Operating Officer. From 1988 to 1994, Mr. O'Connor was with Diasonics, Inc., serving in various positions including Chief Financial Officer. Mr. O'Connor earned a Bachelor of Science in busness administration from the University of California at Berkeley and completed the Executive Education Program at Stanford University Graduate School of Business.
Shawn O’Connor于2018年6月加入公司,担任首席执行官。从2011年至2018年,奥康纳先生担任Entelos的首席执行官,总裁兼董事,Entelos是一家为制药药物开发市场提供独特的定量系统药理软件和服务的提供商。从2002年到2009年,O’Connor先生担任Pharsight Corporation的首席执行官,总裁兼董事长,该公司是一家软件产品和服务的开发商和营销商,帮助制药和生物技术公司改善其药物开发和商业化的决策。从1995年到2000年,奥康纳先生在QRS公司担任多个职位,包括首席财务官、总裁兼首席运营官。1988年至1994年,O’Connor先生在Diasonics,Inc.担任多个职位,包括首席财务官。O’Connor先生在加州大学伯克利分校(University of California at Berkeley)获得工商管理理学学士学位,并在斯坦福大学商学院(Stanford University Graduate School of Business)完成高管教育课程。
Shawn O'Connor,joined the Company in June 2018 as Chief Executive Officer. Mr. O'Connor has more than 31 years of experience in high technology executive management. From 2011 to 2018, Mr. O'Connor was Chief Executive Officer, President, and a director of Entelos Holding Corp., a provider of unique quantitative systems pharmacology software and services to the pharmaceutical drug development market. From 2002 to 2009, Mr. O'Connor served as Chief Executive Officer, President, and Chairman of Pharsight Corporation, a developer and marketer of software products and services that help pharmaceutical and biotechnology companies improve their decision-making in drug development and commercialization. From 1995 to 2000, Mr. O'Connor was with QRS Corporation in various positions including Chief Financial Officer and President and Chief Operating Officer. From 1988 to 1994, Mr. O'Connor was with Diasonics, Inc., serving in various positions including Chief Financial Officer. Mr. O'Connor earned a Bachelor of Science in busness administration from the University of California at Berkeley and completed the Executive Education Program at Stanford University Graduate School of Business.
Will Frederick

Will Frederick于2020年12月加入公司,担任公司首席财务官和秘书。他在开发和实施战略以推动收入增长、提高盈利能力、管理并购活动和实现企业目标方面有着被证明的往绩。他拥有上市公司和私人公司的全球经验,包括Entelos Holding Corp.、Avaya、Pharsight Corporation、华特迪士尼公司和Ford Motor Company等。在加入公司之前,从2015年至今,Frederick先生担任Rightplace Enterprises的总裁兼董事总经理,为多家公司提供C-Suite级别的战略和财务咨询服务。他曾于2014年10月至2015年1月担任Sysorex Global Holdings Corp.的临时首席财务官。2014年4月至2014年9月,他担任Neural ID LLC的首席财务官。他曾担任Entelos Holding Corp.的首席财务官(从2012年1月到2014年1月),当时该公司被Rosa&Co收购。Frederick先生拥有加州州立大学长滩分校(California State University at Long Beach)的工商管理硕士学位和加州州立大学富勒顿分校(California State University at Fullerton)的金融学学士学位。


Will Frederick serves as Executive Vice President & Chief Financial Officer, and Secretary, and joined the Company in December 2020. He has a proven track record of developing and implementing strategies to drive revenue growth, increase profitability, managing merger and acquisition activities, and achieving corporate objectives. He has global experience with both publicly traded and privately held companies including Entelos Holding Corp., Avaya, Pharsight Corporation, The Walt Disney Company, and Ford Motor Company, amongst others. Prior to joining the Company, from 2015 to 2020, Mr. Frederick served as President and Managing Director of RightPlace Enterprises, providing C Suite level strategic and financial consulting services to multiple companies. He served as Interim Chief Financial Officer at Sysorex Global Holdings Corp. from October 2014 to January 2015. He served as Chief Financial Officer at Neural ID LLC from April 2014 to September 2014. He served as Chief Financial Officer of Entelos Holding Corp. from January 2012 to January 2014, at which time it was acquired by Rosa & Co. Mr. Frederick holds an M.B.A degree from California State University at Long Beach and a B.A. degree in Finance from California State University at Fullerton.
Will Frederick于2020年12月加入公司,担任公司首席财务官和秘书。他在开发和实施战略以推动收入增长、提高盈利能力、管理并购活动和实现企业目标方面有着被证明的往绩。他拥有上市公司和私人公司的全球经验,包括Entelos Holding Corp.、Avaya、Pharsight Corporation、华特迪士尼公司和Ford Motor Company等。在加入公司之前,从2015年至今,Frederick先生担任Rightplace Enterprises的总裁兼董事总经理,为多家公司提供C-Suite级别的战略和财务咨询服务。他曾于2014年10月至2015年1月担任Sysorex Global Holdings Corp.的临时首席财务官。2014年4月至2014年9月,他担任Neural ID LLC的首席财务官。他曾担任Entelos Holding Corp.的首席财务官(从2012年1月到2014年1月),当时该公司被Rosa&Co收购。Frederick先生拥有加州州立大学长滩分校(California State University at Long Beach)的工商管理硕士学位和加州州立大学富勒顿分校(California State University at Fullerton)的金融学学士学位。
Will Frederick serves as Executive Vice President & Chief Financial Officer, and Secretary, and joined the Company in December 2020. He has a proven track record of developing and implementing strategies to drive revenue growth, increase profitability, managing merger and acquisition activities, and achieving corporate objectives. He has global experience with both publicly traded and privately held companies including Entelos Holding Corp., Avaya, Pharsight Corporation, The Walt Disney Company, and Ford Motor Company, amongst others. Prior to joining the Company, from 2015 to 2020, Mr. Frederick served as President and Managing Director of RightPlace Enterprises, providing C Suite level strategic and financial consulting services to multiple companies. He served as Interim Chief Financial Officer at Sysorex Global Holdings Corp. from October 2014 to January 2015. He served as Chief Financial Officer at Neural ID LLC from April 2014 to September 2014. He served as Chief Financial Officer of Entelos Holding Corp. from January 2012 to January 2014, at which time it was acquired by Rosa & Co. Mr. Frederick holds an M.B.A degree from California State University at Long Beach and a B.A. degree in Finance from California State University at Fullerton.
Jill Fiedler Kelly

Jill Fiedler Kelly于2014年9月加入公司,当时公司被Cognigen Corporation收购,在那里她曾担任Pharmacometric Services公司的副总裁,以及首席科学官20多年(1992年共同创立公司以来)。在该职位上,她主要负责领导科学咨询集团,确保可交付产品的质量,并代表公司面向新客户。Fiedler-Kelly女士是布法罗大学药物科学系的兼职教授,并于2016年被任命为国际药物计量学会院士。2019年10月,她被任命为Simulations Plus的Cognigen部门总裁。Fiedler-Kelly女士在药物开发中实现群体PK/PD建模和模拟方面拥有超过25年的经验。她还在同行评审的期刊上发表了许多科学论文,在国家和国际研讨会上发表了演讲,并在东海岸人口分析小组等组织担任领导职务,该小组是美国制药科学家协会的人口PK/PD焦点小组,最近在ASCPT董事会任职3年。2016年,她被任命为国际药物计量学会ISOP的研究员。她拥有布法罗大学的统计学学士学位和罗切斯特理工学院的应用和数学统计学硕士学位。


Jill Fiedler Kelly joined the Company in September 2014 with the acquisition of Cognigen Corporation ("Cognigen"), where she had served as the Vice President of Pharmacometric Services and Chief Scientific Officer for over 20 years, since cofounding the company in 1992. In this role, she was primarily responsible for leading the scientific consulting group, ensuring the quality of deliverables and representing the Company to new clients. Ms. Fiedler Kelly is an Adjunct Professor in the Department of Pharmaceutical Sciences at the University at Buffalo and was named a Fellow of the International Society of Pharmacometrics in 2016. In October 2019, she was appointed President of Cognigen, which was merged into the Company in September 2021 and became a division of Simulations Pl. In connection with the Company's internal reorganization in 2025, Ms. Fiedler Kelly was appointed President Services Solutions. Ms. Fiedler Kelly brings approximately 31 years of experience in the implementation of population PK/PD modeling and simulation in drug development. She has also published numero scientific papers in peer revied jnals, has presented at national and international symposia, and has held leadership positions in organizations such as the East Coast Population Analysis Group, the Population PK/PD Foc Group of the American Association of Pharmaceutical Scientists, and the ASCPT Board of Directors. She holds a B.A. degree in Statistics from the University at Buffalo and an M.S. in Applied and Mathematical Statistics from the Rochester Institute of Technology.
Jill Fiedler Kelly于2014年9月加入公司,当时公司被Cognigen Corporation收购,在那里她曾担任Pharmacometric Services公司的副总裁,以及首席科学官20多年(1992年共同创立公司以来)。在该职位上,她主要负责领导科学咨询集团,确保可交付产品的质量,并代表公司面向新客户。Fiedler-Kelly女士是布法罗大学药物科学系的兼职教授,并于2016年被任命为国际药物计量学会院士。2019年10月,她被任命为Simulations Plus的Cognigen部门总裁。Fiedler-Kelly女士在药物开发中实现群体PK/PD建模和模拟方面拥有超过25年的经验。她还在同行评审的期刊上发表了许多科学论文,在国家和国际研讨会上发表了演讲,并在东海岸人口分析小组等组织担任领导职务,该小组是美国制药科学家协会的人口PK/PD焦点小组,最近在ASCPT董事会任职3年。2016年,她被任命为国际药物计量学会ISOP的研究员。她拥有布法罗大学的统计学学士学位和罗切斯特理工学院的应用和数学统计学硕士学位。
Jill Fiedler Kelly joined the Company in September 2014 with the acquisition of Cognigen Corporation ("Cognigen"), where she had served as the Vice President of Pharmacometric Services and Chief Scientific Officer for over 20 years, since cofounding the company in 1992. In this role, she was primarily responsible for leading the scientific consulting group, ensuring the quality of deliverables and representing the Company to new clients. Ms. Fiedler Kelly is an Adjunct Professor in the Department of Pharmaceutical Sciences at the University at Buffalo and was named a Fellow of the International Society of Pharmacometrics in 2016. In October 2019, she was appointed President of Cognigen, which was merged into the Company in September 2021 and became a division of Simulations Pl. In connection with the Company's internal reorganization in 2025, Ms. Fiedler Kelly was appointed President Services Solutions. Ms. Fiedler Kelly brings approximately 31 years of experience in the implementation of population PK/PD modeling and simulation in drug development. She has also published numero scientific papers in peer revied jnals, has presented at national and international symposia, and has held leadership positions in organizations such as the East Coast Population Analysis Group, the Population PK/PD Foc Group of the American Association of Pharmaceutical Scientists, and the ASCPT Board of Directors. She holds a B.A. degree in Statistics from the University at Buffalo and an M.S. in Applied and Mathematical Statistics from the Rochester Institute of Technology.
Jonathan Chauvin

Jonathan Chauvin,2020年4月加入公司,担任Lixoft总裁,Lixoft是一家被Simulations Plus收购的建模和仿真公司。在担任这一职务之前,Jonathan Chauvin曾在IFP Energies Nouvelles担任研究工程师、项目经理和产品经理等职务。应用和产品在移动领域(热能、混合动力和电动汽车)和能源(作为陆上风力和海洋系统的一部分)。在此期间,他申请了三十多项专利,并指导了二十篇在裁判委员会的报纸文章中发表的文章,以及这些领域的五十篇会议论文。关于公司内部重组,Chauvin博士被任命为CPP Software的业务部门总裁。Jonathan Chauvin于2003年毕业于MINES ParisTech的土木工程师,并于2006年在Applied MINES ParisTech获得数学博士学位。他在2007年获得了“最佳论文巴黎科技”奖。Jonathan Chauvin博士是一位应用数学家。


Jonathan Chauvin joined the Company in April 2020 as the President of Lixoft, a modeling and simulation company acquired by Simulations Pl. Prior to this role, Jonathan Chauvin held positions as a research engineer, project manager, and product manager at IFP Energies nouvelles. The applications and products re in the field of mobility (thermal, hybrid, and electric vehicles) and energy (as part of onshore wind and marine systems). During this period, he filed more than thirty patents and directed tnty publications in refereed committees' newspaper articles, and fifty conference papers in these areas. In connection with the Company's internal reorganization, Dr. Chauvin was appointed Co Chief Product and Technology Officer May 30, 2025. Jonathan Chauvin graduated as a civil engineer at MINES ParisTech in 2003 and obtained his Ph.D. in Mathematics at Applied MINES ParisTech in 2006. He received the award for "Best thesis ParisTech" in 2007. Dr. Jonathan Chauvin is an applied mathematician.
Jonathan Chauvin,2020年4月加入公司,担任Lixoft总裁,Lixoft是一家被Simulations Plus收购的建模和仿真公司。在担任这一职务之前,Jonathan Chauvin曾在IFP Energies Nouvelles担任研究工程师、项目经理和产品经理等职务。应用和产品在移动领域(热能、混合动力和电动汽车)和能源(作为陆上风力和海洋系统的一部分)。在此期间,他申请了三十多项专利,并指导了二十篇在裁判委员会的报纸文章中发表的文章,以及这些领域的五十篇会议论文。关于公司内部重组,Chauvin博士被任命为CPP Software的业务部门总裁。Jonathan Chauvin于2003年毕业于MINES ParisTech的土木工程师,并于2006年在Applied MINES ParisTech获得数学博士学位。他在2007年获得了“最佳论文巴黎科技”奖。Jonathan Chauvin博士是一位应用数学家。
Jonathan Chauvin joined the Company in April 2020 as the President of Lixoft, a modeling and simulation company acquired by Simulations Pl. Prior to this role, Jonathan Chauvin held positions as a research engineer, project manager, and product manager at IFP Energies nouvelles. The applications and products re in the field of mobility (thermal, hybrid, and electric vehicles) and energy (as part of onshore wind and marine systems). During this period, he filed more than thirty patents and directed tnty publications in refereed committees' newspaper articles, and fifty conference papers in these areas. In connection with the Company's internal reorganization, Dr. Chauvin was appointed Co Chief Product and Technology Officer May 30, 2025. Jonathan Chauvin graduated as a civil engineer at MINES ParisTech in 2003 and obtained his Ph.D. in Mathematics at Applied MINES ParisTech in 2006. He received the award for "Best thesis ParisTech" in 2007. Dr. Jonathan Chauvin is an applied mathematician.
Josh Fohey

Josh Fohey于2019年3月加入公司。作为战略领导者,Josh专注于使CTomers的短期目标和长期研究目标与适当的科学咨询资源和软件开发战略保持一致。Josh在Simulations PL领导服务运营、软件运营和QMS团队。在获得威斯康星大学君越大学生物化学学位后,Josh在药物开发行业担任过多个职务,包括药代动力学科学家、项目经理、BINIS开发总监以及科学和运营领导。从早期发现到早期临床开发的支持项目的角色的多样化背景使Josh能够更好地理解客户的开发项目快速演变的需求,无论是小型生物技术公司、大型制药公司,还是beten的任何合作伙伴。


Josh Fohey joined the Company in March 2019. As a strategic leader, Josh foces on aligning ctomers' short term objectives and long term research goals to the appropriate scientific consulting resces and software development strategies. Josh leads the service operations, software operations, and QMS teams at Simulations Pl. After receiving a degree in Biochemistry from the University of Wisconsin LaCrosse, Josh has filled many roles in the Pharmaceutical development indtry, including pharmacokinetic scientist, project manager, biness development director, and scientific and operational leadership. The diverse background of roles supporting programs from early discovery through early clinical development positions Josh to better understand the quickly evolving needs of the development programs of clients whether small biotech, large pharma, or any partner in beten.
Josh Fohey于2019年3月加入公司。作为战略领导者,Josh专注于使CTomers的短期目标和长期研究目标与适当的科学咨询资源和软件开发战略保持一致。Josh在Simulations PL领导服务运营、软件运营和QMS团队。在获得威斯康星大学君越大学生物化学学位后,Josh在药物开发行业担任过多个职务,包括药代动力学科学家、项目经理、BINIS开发总监以及科学和运营领导。从早期发现到早期临床开发的支持项目的角色的多样化背景使Josh能够更好地理解客户的开发项目快速演变的需求,无论是小型生物技术公司、大型制药公司,还是beten的任何合作伙伴。
Josh Fohey joined the Company in March 2019. As a strategic leader, Josh foces on aligning ctomers' short term objectives and long term research goals to the appropriate scientific consulting resces and software development strategies. Josh leads the service operations, software operations, and QMS teams at Simulations Pl. After receiving a degree in Biochemistry from the University of Wisconsin LaCrosse, Josh has filled many roles in the Pharmaceutical development indtry, including pharmacokinetic scientist, project manager, biness development director, and scientific and operational leadership. The diverse background of roles supporting programs from early discovery through early clinical development positions Josh to better understand the quickly evolving needs of the development programs of clients whether small biotech, large pharma, or any partner in beten.
Erik Guffrey

Erik Guffrey于2024年6月加入该公司,作为其收购Pro FICiency的一部分。凭借对设计和构建令人愉悦的可扩展解决方案的热情,Erik带来了20多年的工程师和数字产品开发人员。他有近十年的行政领导职位,拥有从战略产品定位到战术特征开发以及beten中的一切的深度技能。埃里克在其职业生涯的早期阶段,曾在商业房地产私募股权、一家对冲基金和两家金融科技初创公司的金融行业工作。最近,他领导了数字产品和创意资本工作室Fugitive Labs,后者为临床试验indtry构建了三个产品—— Trial Portals,一个协议文档管理平台;Study Recruiter,一个匹配算法beten研究者和试验;和Study Ledger,一个研究者支付跟踪平台。随着Pro FICiency收购这些产品,Erik加入Pro FICiency领导产品开发工作。Guffrey先生于2025年5月30日被任命为联合首席产品和技术官。Guffrey先生拥有北卡罗来纳州立大学工程学学士学位。


Erik Guffrey joined the Company in June 2024 as part of its acquisition of Pro ficiency. He has nearly a decade in executive leadership positions and possesses a depth of skills ranging from strategic product positioning to tactical feature development and everything in beten. Erik spent the early part of his career working in the financial indtry for commercial real estate private equity, a hedge fund, and two fin tech startups. Most recently he led digital product and creative capital studio, Fugitive Labs, who built three products for the clinical trials indtry — Trial Portals, a protocol documentation management platform; Study Recruiter, a matching algorithm beten investigators and trials; and Study Ledger, an investigator payment tracking platform. With Pro ficiency's acquisition of these products, Erik joined Pro ficiency to lead product development efforts. Mr. Guffrey was appointed Co Chief Product and Technology Officer May 30, 2025. Mr. Guffrey holds a B.S degree in engineering from NC State University.
Erik Guffrey于2024年6月加入该公司,作为其收购Pro FICiency的一部分。凭借对设计和构建令人愉悦的可扩展解决方案的热情,Erik带来了20多年的工程师和数字产品开发人员。他有近十年的行政领导职位,拥有从战略产品定位到战术特征开发以及beten中的一切的深度技能。埃里克在其职业生涯的早期阶段,曾在商业房地产私募股权、一家对冲基金和两家金融科技初创公司的金融行业工作。最近,他领导了数字产品和创意资本工作室Fugitive Labs,后者为临床试验indtry构建了三个产品—— Trial Portals,一个协议文档管理平台;Study Recruiter,一个匹配算法beten研究者和试验;和Study Ledger,一个研究者支付跟踪平台。随着Pro FICiency收购这些产品,Erik加入Pro FICiency领导产品开发工作。Guffrey先生于2025年5月30日被任命为联合首席产品和技术官。Guffrey先生拥有北卡罗来纳州立大学工程学学士学位。
Erik Guffrey joined the Company in June 2024 as part of its acquisition of Pro ficiency. He has nearly a decade in executive leadership positions and possesses a depth of skills ranging from strategic product positioning to tactical feature development and everything in beten. Erik spent the early part of his career working in the financial indtry for commercial real estate private equity, a hedge fund, and two fin tech startups. Most recently he led digital product and creative capital studio, Fugitive Labs, who built three products for the clinical trials indtry — Trial Portals, a protocol documentation management platform; Study Recruiter, a matching algorithm beten investigators and trials; and Study Ledger, an investigator payment tracking platform. With Pro ficiency's acquisition of these products, Erik joined Pro ficiency to lead product development efforts. Mr. Guffrey was appointed Co Chief Product and Technology Officer May 30, 2025. Mr. Guffrey holds a B.S degree in engineering from NC State University.
Viera Lukacova

Viera Lukacova于2005年5月加入公司。卢卡科娃博士在公司任职期间,她曾在GastroPL上做出贡献,DDDPL,and MembranePL软件包就像对建模研究的贡献一样,帮助公司在药物开发过程的不同阶段以及与监管机构的互动中进行药物开发计划。2025年5月,卢卡科娃博士被任命为首席科学官。她拥有斯洛伐克科技大学生物化学和生物技术硕士学位和北达科他州立大学药物科学博士学位。


Viera Lukacova joined the Company in May 2005. During Dr. Lukacova's time with the company, she has contributed on the GastroPl, DDDPl, and MembranePl software packages as ll as contributing to modeling studies helping companies with their drug development programs in different stages of drug development process and interactions with regulatory agencies. In May 2025, Dr. Lukacova was appointed to Chief Scientific Officer. She holds a M.S. degree in Biochemistry and Biotechnology from Slovak University of Technology and a Ph.D. in Pharmaceutical Sciences from North Dakota State University.
Viera Lukacova于2005年5月加入公司。卢卡科娃博士在公司任职期间,她曾在GastroPL上做出贡献,DDDPL,and MembranePL软件包就像对建模研究的贡献一样,帮助公司在药物开发过程的不同阶段以及与监管机构的互动中进行药物开发计划。2025年5月,卢卡科娃博士被任命为首席科学官。她拥有斯洛伐克科技大学生物化学和生物技术硕士学位和北达科他州立大学药物科学博士学位。
Viera Lukacova joined the Company in May 2005. During Dr. Lukacova's time with the company, she has contributed on the GastroPl, DDDPl, and MembranePl software packages as ll as contributing to modeling studies helping companies with their drug development programs in different stages of drug development process and interactions with regulatory agencies. In May 2025, Dr. Lukacova was appointed to Chief Scientific Officer. She holds a M.S. degree in Biochemistry and Biotechnology from Slovak University of Technology and a Ph.D. in Pharmaceutical Sciences from North Dakota State University.
John A. DiBella

John A. DiBella于2003年6月加入公司,担任建模与模拟科学家,最初致力于GastroPlus和DDDPlus软件平台的开发,并在为赞助公司提供咨询项目方面担任技术负责人。2005年,DiBella先生进入市场和销售部,并担任实地科学家,最终接管了市场和销售部,并担任主任至2012年2月。迪贝拉先生于2012年3月被任命为公司市场与销售副总裁。2017年9月,DiBella先生被任命为Simulations Plus部门的总裁,目前他领导该部门的战略工作,并继续主持研讨会和出席全球会议。DiBella先生拥有凯斯西储大学生物医学工程学士和硕士学位。


John A. DiBella joined the Company in June 2003 as a Modeling & Simulations Scientist, initially spending time working on the development of the GastroPl and DDDPl software platforms, as ll as serving as a technical lead on consulting projects for sponsor companies. In 2005, Mr. DiBella moved to the Marketing and Sales Department, and worked as a Field Scientist, where he eventually took over the Marketing and Sales Department and worked as Director until February 2012. Mr. DiBella was appointed Vice President of Marketing and Sales of the Company in March 2012. In September 2017, Mr. DiBella was appointed President of the Simulations Pl Division, and in connection with the Company's internal reorganization, his title was changed to Biness Unit President of PBPK and Cheminformatics Solutions. In June 2025, Mr. DiBella was appointed Chief Revenue Officer of Simulations Pl, Inc. Mr. DiBella holds B.S. degree and Master's degree in biomedical engineering from Case stern Reserve University.
John A. DiBella于2003年6月加入公司,担任建模与模拟科学家,最初致力于GastroPlus和DDDPlus软件平台的开发,并在为赞助公司提供咨询项目方面担任技术负责人。2005年,DiBella先生进入市场和销售部,并担任实地科学家,最终接管了市场和销售部,并担任主任至2012年2月。迪贝拉先生于2012年3月被任命为公司市场与销售副总裁。2017年9月,DiBella先生被任命为Simulations Plus部门的总裁,目前他领导该部门的战略工作,并继续主持研讨会和出席全球会议。DiBella先生拥有凯斯西储大学生物医学工程学士和硕士学位。
John A. DiBella joined the Company in June 2003 as a Modeling & Simulations Scientist, initially spending time working on the development of the GastroPl and DDDPl software platforms, as ll as serving as a technical lead on consulting projects for sponsor companies. In 2005, Mr. DiBella moved to the Marketing and Sales Department, and worked as a Field Scientist, where he eventually took over the Marketing and Sales Department and worked as Director until February 2012. Mr. DiBella was appointed Vice President of Marketing and Sales of the Company in March 2012. In September 2017, Mr. DiBella was appointed President of the Simulations Pl Division, and in connection with the Company's internal reorganization, his title was changed to Biness Unit President of PBPK and Cheminformatics Solutions. In June 2025, Mr. DiBella was appointed Chief Revenue Officer of Simulations Pl, Inc. Mr. DiBella holds B.S. degree and Master's degree in biomedical engineering from Case stern Reserve University.